Neothetics, Inc. is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. LIPO-202 is a first-in-class injectable formulation of the long-acting Beta2-adrenergic receptor agonist, and salmeterol xinafoate, which is an active ingredient in the United States Food and Drug Administration inhaled products, such as SEREVENT DISKUS, ADVAIR HFA and ADVAIR DISKUS. The Company is developing a product candidate, LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:NEOT
- CUSIP: N/A
- Web: www.neothetics.com
- Market Cap: $4.99 million
- Outstanding Shares: 13,831,000
- 50 Day Moving Avg: $0.38
- 200 Day Moving Avg: $1.27
- 52 Week Range: $0.30 - $2.63
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.86
- P/E Growth: 0.0000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.47 per share
- Price / Book: 0.77
- EBIDTA: ($9,540,000.00)
- Return on Equity: -98.61%
- Return on Assets: -86.58%
- Current Ratio: 4.76%
- Quick Ratio: 4.76%
- Average Volume: 931,211 shs.
- Beta: 2.33
- Short Ratio: 0.61
Frequently Asked Questions for Neothetics (NASDAQ:NEOT)
What is Neothetics' stock symbol?
Neothetics trades on the NASDAQ under the ticker symbol "NEOT."
How were Neothetics' earnings last quarter?
Neothetics, Inc. (NASDAQ:NEOT) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). View Neothetics' Earnings History.
When will Neothetics make its next earnings announcement?
Are investors shorting Neothetics?
Neothetics saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 1,280,217 shares, an increase of 48.6% from the July 31st total of 861,273 shares. Based on an average daily volume of 902,529 shares, the days-to-cover ratio is currently 1.4 days. Currently, 14.6% of the shares of the company are short sold.
Who are some of Neothetics' key competitors?
Some companies that are related to Neothetics include Aegerion Pharmaceuticals (AEGR), Amryt Pharma PLC (FAST), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), CoLucid Pharmaceuticals (CLCD), Forest Laboratories (FRX), Hi-Tech Pharmacal (HITK), Innocoll Holdings PLC (INNL), Optimer Pharmaceuticals (OPTR), Questcor Pharmaceuticals (QCOR), Sagent Pharmaceuticals (SGNT), Santarus (SNTS), Shire PLC (SHPG), Shire Viropharma (VPHM), SkyePharma PLC (SKP), Theravance Biopharma (TBPHV), Valeant Pharmaceuticals Intl (BVF) and Warner Chilcott Plc (WCRX).
Who are Neothetics' key executives?
Neothetics' management team includes the folowing people:
- Susan A. Knudson, Chief Financial Officer
- Maria Feldman, Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance
- Kim P. Kamdar Ph.D., Lead Independent Director
- Martha J. Demski, Independent Director
- Maxim Gorbachev, Independent Director
- Jeffrey M. Nugent, Independent Director
When did Neothetics IPO?
(NEOT) raised $60 million in an initial public offering (IPO) on Thursday, November 20th 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Piper Jaffray and Guggenheim Securities acted as the underwriters for the IPO and Needham & Company was co-manager.
Who owns Neothetics stock?
Neothetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu KCG Holdings LLC (2.01%). Company insiders that own Neothetics stock include Alta Partners Viii, LP, Kenneth W Locke and Susan A Knudson. View Institutional Ownership Trends for Neothetics.
Who bought Neothetics stock? Who is buying Neothetics stock?
How do I buy Neothetics stock?
Shares of Neothetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neothetics' stock price today?
MarketBeat Community Rating for Neothetics (NASDAQ NEOT)MarketBeat's community ratings are surveys of what our community members think about Neothetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Neothetics stock can currently be purchased for approximately $0.36.
Consensus Ratings for Neothetics (NASDAQ:NEOT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Neothetics (NASDAQ:NEOT)
(Data available from 9/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|12/15/2015||Piper Jaffray Companies||Downgrade||Overweight -> Neutral||N/A|
|12/15/2015||Needham & Company LLC||Downgrade||Buy -> Hold||N/A|
Earnings History for Neothetics (NASDAQ:NEOT)Earnings History by Quarter for Neothetics (NASDAQ NEOT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Neothetics (NASDAQ:NEOT)
Current Year EPS Consensus Estimate: $-0.610 EPS
Next Year EPS Consensus Estimate: $-0.420 EPS
Dividend History for Neothetics (NASDAQ:NEOT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Neothetics (NASDAQ:NEOT)
Insider Ownership Percentage: 39.20%Insider Trades by Quarter for Neothetics (NASDAQ:NEOT)
Institutional Ownership Percentage: 4.65%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/30/2015||Alta Partners Viii, L.P.||Insider||Sell||797,987||$1.51||$1,204,960.37|| |
|12/29/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||493,654||$1.53||$755,290.62|| |
|12/28/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||54,333||$1.59||$86,389.47|| |
|12/17/2015||Kenneth W. Locke||Insider||Sell||598||$1.26||$753.48|| |
|12/17/2015||Susan A. Knudson||CFO||Sell||1,005||$1.26||$1,266.30|| |
|12/15/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||529,261||$1.44||$762,135.84|| |
|11/18/2015||Kenneth W. Locke||insider||Sell||6,098||$8.30||$50,613.40|| |
|9/18/2015||Christopher Kemmerer||VP||Sell||1,000||$12.20||$12,200.00|| |
|9/1/2015||Susan A. Knudson||CFO||Sell||3,000||$11.33||$33,990.00|| |
|3/19/2015||George W Mahaffey||CEO||Buy||1,000||$7.76||$7,760.00|| |
|11/25/2014||Daniel Janney||Director||Sell||149,286||$14.00||$2,090,004.00|| |
|11/25/2014||Rmi Investments S.A.R.L.||Major Shareholder||Buy||70,000||$14.00||$980,000.00|| |
Headline Trends for Neothetics (NASDAQ:NEOT)
Latest Headlines for Neothetics (NASDAQ:NEOT)
|Neothetics Inc (NEOT): How Does It Impact Your Portfolio?|
finance.yahoo.com - September 19 at 2:38 AM
|Short Interest in Neothetics, Inc. (NEOT) Increases By 48.6%|
www.americanbankingnews.com - August 28 at 1:20 AM
|BRIEF-Neothetics posts Q2 loss per share $0.20|
www.reuters.com - August 12 at 8:14 PM
|Neothetics, Inc. (NEOT) Releases Earnings Results, Meets Estimates|
www.americanbankingnews.com - August 11 at 7:54 PM
|Neothetics Provides Business Update and Reports Second Quarter 2017 Financial Results|
finance.yahoo.com - August 11 at 6:53 AM
|Neothetics Announces Review of Strategic Alternatives|
finance.yahoo.com - July 11 at 3:27 AM
|Neothetics stock plummets 66% on news of negative results for fat-reduction drug|
www.marketwatch.com - June 27 at 6:53 PM
|Neothetics Inc. (NEOT) Sank To A 10-Month Low After Phase 2 Study Failed|
www.rttnews.com - June 27 at 6:53 PM
|Neothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous Fat|
finance.yahoo.com - June 26 at 8:49 AM
|Neothetics stock halted on news of negative results for fat-reduction drug|
finance.yahoo.com - June 26 at 8:49 AM
|Neothetics Inc (NEOT) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS|
www.americanbankingnews.com - May 12 at 2:46 PM
|Neothetics Provides Business Update and Reports First Quarter 2017 Financial Results|
finance.yahoo.com - May 11 at 9:28 AM
|Neothetics to Provide a Business Update and Release First Quarter 2017 Financial Results Thursday, May 11th, 2017|
finance.yahoo.com - May 4 at 11:25 AM
|Neothetics (NEOT) Getting Somewhat Favorable News Coverage, Report Finds|
www.americanbankingnews.com - April 13 at 6:15 PM
|Neothetics Posts Solid Win on Patent Approval|
finance.yahoo.com - April 7 at 7:13 PM
|NEOTHETICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - April 3 at 6:07 PM
|Q4 2016 Neothetics Inc Earnings Release - Before Market Open|
us.rd.yahoo.com - March 23 at 7:18 PM
|Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results|
us.rd.yahoo.com - March 23 at 7:18 PM
|Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat|
finance.yahoo.com - March 20 at 10:01 AM
|Neothetics to Provide a Business Update and Release Fourth Quarter 2016 Financial Results Thursday, March 23, 2017|
finance.yahoo.com - March 16 at 9:04 AM
|NEOTHETICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - March 7 at 6:37 PM
|Form SC 13G/A Neothetics, Inc. Filed by: DRILL CRAIG A|
www.streetinsider.com - January 6 at 7:29 PM
|Neothetics (NEOT) Begins Phase II Study on Lead Candidate|
www.zacks.com - December 28 at 10:05 AM
|Neothetics (NEOT) Phase 2 Proof of Concept Trial for LIPO-202 Initiated for Double Chin|
www.streetinsider.com - December 24 at 6:18 PM
|Neothetics (NEOT) Leaped as New Drug Trial Commences|
www.baystreet.ca - December 23 at 8:17 PM
|NEOTHETICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement|
biz.yahoo.com - September 23 at 5:55 PM
|Neothetics Provides Business Update and Reports Second Quarter 2016 Financial Results|
www.nasdaq.com - August 11 at 9:37 AM
|NEOTHETICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - June 17 at 8:01 AM
|NEOTHETICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;|
biz.yahoo.com - June 6 at 8:01 AM
|NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits|
biz.yahoo.com - May 12 at 8:01 AM
|Q1 2016 Neothetics Inc Earnings Release - Before Market Open|
biz.yahoo.com - May 12 at 7:07 AM
|Stocks To Watch: Investors Are Considering These on Monday April 25th|
finance.yahoo.com - April 25 at 11:30 AM
|NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal|
biz.yahoo.com - February 18 at 4:08 PM
|Neothetics Announces Leadership Change and Preliminary Update on LIPO-202|
finance.yahoo.com - February 18 at 4:00 PM
|Why Neothetics Is Getting Destroyed|
247wallst.com - December 15 at 1:15 PM
|Breaking: This Biotech Just Got Blown Up on a Late Stage Trial|
finance.yahoo.com - December 14 at 5:54 PM
|NEOTHETICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - December 14 at 5:02 PM
|NEOTHETICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events|
biz.yahoo.com - December 10 at 4:39 PM
|NEOTHETICS, INC. Financials|
finance.yahoo.com - December 8 at 1:17 PM
|NEOTHETICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
biz.yahoo.com - December 1 at 5:21 PM
Neothetics (NEOT) Chart for Friday, September, 22, 2017